002693 Stock Overview
Hainan Shuangcheng Pharmaceuticals Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.07 |
| 52 Week High | CN¥40.98 |
| 52 Week Low | CN¥3.67 |
| Beta | 0.17 |
| 1 Month Change | -28.70% |
| 3 Month Change | -61.15% |
| 1 Year Change | 160.36% |
| 3 Year Change | 195.70% |
| 5 Year Change | 93.63% |
| Change since IPO | 66.39% |
Recent News & Updates
Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Popularity With Investors Under Threat As Stock Sinks 30%
Dec 22
Is Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Using Too Much Debt?
Nov 27Recent updates
Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Popularity With Investors Under Threat As Stock Sinks 30%
Dec 22Is Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Using Too Much Debt?
Nov 27Subdued Growth No Barrier To Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s (SZSE:002693) Price
Aug 03Getting In Cheap On Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) Is Unlikely
Apr 15Shareholder Returns
| 002693 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.8% | 0.2% | -0.9% |
| 1Y | 160.4% | 12.8% | 22.0% |
Return vs Industry: 002693 exceeded the CN Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: 002693 exceeded the CN Market which returned 18.4% over the past year.
Price Volatility
| 002693 volatility | |
|---|---|
| 002693 Average Weekly Movement | 12.1% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 4.0% |
Stable Share Price: 002693's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 002693's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 474 | Jianming Li | www.shuangchengmed.com |
Hainan Shuangcheng Pharmaceuticals Co., Ltd. provides peptide, lyophilized, oncology, oral dosage, and other injection cartridge pharmaceutical products worldwide. The company offers thymalfasin, thymapentin, bortezmib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, and exenatide and sodium ferulate for injections, as well as vitamin B6. Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. Fundamentals Summary
| 002693 fundamental statistics | |
|---|---|
| Market cap | CN¥5.42b |
| Earnings (TTM) | -CN¥86.96m |
| Revenue (TTM) | CN¥180.64m |
30.0x
P/S Ratio-62.3x
P/E RatioIs 002693 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002693 income statement (TTM) | |
|---|---|
| Revenue | CN¥180.64m |
| Cost of Revenue | CN¥79.39m |
| Gross Profit | CN¥101.25m |
| Other Expenses | CN¥188.21m |
| Earnings | -CN¥86.96m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 29, 2025
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 56.05% |
| Net Profit Margin | -48.14% |
| Debt/Equity Ratio | 44.9% |
How did 002693 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 04:18 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hainan Shuangcheng Pharmaceuticals Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Yao | Everbright Securities Co. Ltd. |
| Yun Li | Guodu Securities Co. |